Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
UNAIDS.
Report on the Global AIDS Epidemic 2009.
UNAIDS, (2009),
[2.]
Centers for Disease Control and Prevention.
HIV prevalence estimates—United States, 2006.
MMWR Morb Mortal Wkly Rep, 57 (2008), pp. 1073-1076
[3.]
M.L. Campsmith, P.H. Rhodes, H.I. Hall.
Estimated prevalence of undiagnosed HIV infection: U.S. end of 2006.
16th Conference on Retroviruses and Opportunistic Infections 2009,
[4.]
M.L. Campsmith, P.H. Rhodes, H.I. Hall, T.H. Green.
Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006.
J Acquir Immune Defic Syndr, 53 (2010), pp. 619-624
[5.]
G. Marks, N. Crepaz, R.S. Janssen.
Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA.
AIDS, 20 (2006), pp. 1447-1450
[6.]
G. Marks, N. Crepaz, J.W. Senterfitt, R.S. Janssen.
Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs.
J Acquir Immune Defic Syndr, 39 (2005), pp. 446-453
[7.]
L.S. Weinhardt, M.P. Carey, B.T. Johnson, N.L. Bickham.
Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997.
Am J Public Health, 89 (1999), pp. 1397-1405
[8.]
Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, December 1, 2009. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
[9.]
P.E. Sax.
Assessing risk for cardiovascular disease in patients with human immunodeficiency virus: why it matters.
Circulation., 121 (2010), pp. 620-622
[10.]
V.A. Triant, H. Lee, C. Hadigan, S.K. Grinspoon.
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with. uman immunodeficiency virus disease.
J Clin Endocrinol Metab, 92 (2007), pp. 2506-2512
[11.]
K.A. Lichtenstein, K. Buchacz, A. Moorman, Analysis of cardiovascular risk factors in the HIV. Outpatient Study (HOPS) cohort, et al.
Abstracts of the Thirteenth Conference on Retroviruses Opportunistic Infections Denver FCO. Foundation for Retrovirology and Human Health.
Alexandria Va, (2006),
[12.]
S. Das.
Risk of cardiovascular disease in HIV-infected patients.
J Antimicrob Chemother, 65 (2010), pp. 386-389
[13.]
S.K. Gupta, J.A. Eustace, J.A. Winston, et al.
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Disease Society of America.
Clin Infect Dis, 40 (2005), pp. 1559-1585
[14.]
A. Winston, J. Amin, P. Mallon, et al.
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
HIV Med, 7 (2006), pp. 105-111
[15.]
P. Labarga, P. Barreiro, L. Martin-Carbonero, et al.
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV. patients treated with tenofovir.
AIDS, 23 (2009), pp. 689-696
[16.]
J.E. Gallant, J.A. Winston, E. DeJesus, et al.
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
AIDS, 22 (2008), pp. 2155-2163
[17.]
T. Powles, D. Robinson, J. Stebbing, et al.
Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
J Clin Oncol, 27 (2009), pp. 884-890
[18.]
A. Kreuter, U. Wieland.
Human papillomavirusassociated disease in HIV-infected men who have sex with men.
Curr Opin Infect Dis, 22 (2009), pp. 109-114
[19.]
D.M. Parkin.
The global health burden of infection associated cancers in the year 2002.
Int J Cancer, 118 (2006), pp. 3030-3044
[20.]
J. Palefsky.
Human papillomavirus and anal neoplasia.
Curr HIV/AIDS Rep, 5 (2008), pp. 78-85
[21.]
HIV Clinical Resource. Human papillomavirus. http://www.hivguidelines.org/GuideLine.aspx?guideLineID=102.
Copyright © 2011. Lippincott Williams & Wilkins